Nivolumab Clinical Trials
A listing of Nivolumab medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 12 clinical trials
Multiple Phase 1 Safety Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558).
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
This study is being done to test the safety of combining Entinostat with Nivolumab and Ipilimumab. It will also measure the percentage of patients whose tumor shrank after receiving Entinostat with Nivolumab and Ipilimumab.
- 0 views
- 19 Feb, 2024
- 1 location
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- 0 views
- 19 Feb, 2024
- 1 location
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
This phase II trial studies how well axitinib and nivolumab works in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body.
- 0 views
- 19 Feb, 2024
- 1 location
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ipilimumab when given after completing chemotherapy and radiation.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
The purpose of this study is to evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized).
- 0 views
- 19 Feb, 2024
- 1 location
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- 0 views
- 19 Feb, 2024
- 1 location
Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2